### Meglumine antimoniate

**Indication**  
Cutaneous leishmaniasis  
**ICD11 code:** 1F54.1

**Medicine type**  
Chemical agent

**List type**  
Core (EML) (EMLc)

**Formulations**  
Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule

**EML status history**  
- First added in 1987 (TRS 770)
- Changed in 1989 (TRS 796)
- Changed in 2002 (TRS 914)
- Changed in 2007 (TRS 950)
- Changed in 2009 (TRS 958)
- Changed in 2009 (TRS 958)
- Changed in 2023 (TRS 1049)

**Sex**  
All

**Age**  
Also recommended for children

**Therapeutic alternatives**  
The recommendation is for this specific medicine

**Patent information**  
Patents have expired in most jurisdictions  
[Read more about patents.](#)

**Wikipedia**  
[Meglumine antimoniate](#)

**DrugBank**  
[Meglumine antimoniate (Pentavalent Antimony)](#)

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for sodium stibogluconate / meglumine antimoniate on the EML and EMLc be amended to list each medicine separately with updated dosage form descriptions as follows: Sodium stibogluconate: Injection: 100 mg/mL in 30 mL vial  
Meglumine antimoniate: Injection: 1.5 g/5 mL in 5 mL ampoule